Board

Brenda Reynolds, Executive Chairman

Brenda Reynolds was, until 2015, a founder and the Chief Operating Officer of Convergence Pharmaceuticals and a key member of the deal team in its sale to Biogen. She was previously a founder, director and COO of PowderMed Ltd which was spun out of Chiron in 2004 and successfully sold to Pfizer in 2006. Prior to this Brenda was Vice President of Portfolio & Programme Management at PowderJect Pharmaceuticals plc.

In her 35 years of experience in R & D management she has held a number of senior positions in major international healthcare companies including Pfizer, Scotia Holdings PLC, G D Searle. She is currently an NED of iQur and BQR Consulting Ltd and a member of the BIA Board. Brenda holds a degree in Toxicology, and is a Chartered Director and Fellow of the IOD.

Simon Tate, Non-Executive Director

Simon Tate has more than 25 years of experience in drug discovery and development, 20 years of which in ion channels and pain. Simon was instrumental to the acquisition of Convergence Pharmaceuticals’ clinical assets from GSK, where he was previously Vice President, Pain and Epilepsy Discovery Performance Unit. He continued to head up the Convergence Development team within Biogen post their acquisition of the company in 2015.

Simon led a paradigm shift for ion channel screening in GSK, implementing new platform technology through collaborations and alliances. Several ion channel projects have now progressed into the clinic as a consequence of this initiative and investment in ion channel research.

Allan Marchington, Apposite Capital

Dr Allan Marchington was a founder and Partner at Apposite Capital and he serves or has served on the Boards of a number of UK and US based companies including Ambit Biosciences, Ambrx Inc., RuiYi Inc., Convergence Pharmaceuticals Ltd. Allan was formerly at Abingworth Management and prior to this was a member of Millennium Pharmaceuticals management team as a Senior Vice President with responsibility for all technology investments. Allan also served as Chairman of Millennium Pharmaceuticals in Europe. Allan joined Millennium following their acquisition in July 2000 of Cambridge Discovery Chemistry, where he was CEO and founder. Allan began his career as a medicinal chemist at Pfizer Central Research and was a Board member of the BIA for 6 years.

Liam Ratcliffe, New Leaf Venture Partners

Liam Ratcliffe is a Venture Partner and concentrates on New Leaf Venture Partners’ biopharmaceuticals efforts. Liam joined New Leaf in September 2008. Liam most recently served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions at Pfizer included Vice President of Exploratory Development for the Mid-West region, and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. As Head of Neurosciences, Liam was responsible for the development of several successful late-stage projects and marketed products, including PD 332, 334, Lyrica, Chantix and Geodon. In previous roles, he gained extensive experience in early drug development and translational research across multiple therapeutic areas, including inflammation, pain, cardiovascular disease, infectious diseases and genitor-urinary medicine.

Liam began his career in the pharmaceutical industry in a medical marketing role at Roche in South Africa. He received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and additional teaching hospitals in Cape Town, South Africa.

Kate Bingham, Managing Partner – SV Life Sciences

Kate Bingham joined SVLS in 1991. Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Alantos, Auxilium, ESBATech, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed, RespiVert and current investments including Autifony, Bicycle, Convergence, EUSA and TopiVert. Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA.